Evidence map›Paper›PMID 28653260›Full record

ArticleInternational journal of clinical pharmacy2017

Contributions of community pharmacists to patients on antidepressants-a qualitative study among key informants.

Laurence Guillaumie, Jocelyne Moisan, Jean-Pierre Grégoire, Denis Villeneuve, Clément Beaucage, Lilianne Bordeleau, Sophie Lauzier

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical pharmacy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Patient perspectives on the role of community pharmacists for antidepressant treatment: A qualitative study.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Laurence GuillaumieChair on Adherence to Treatments, Université Laval, Québec, QC, Canada.
Jocelyne MoisanChair on Adherence to Treatments, Université Laval, Québec, QC, Canada.
Jean-Pierre GrégoireChair on Adherence to Treatments, Université Laval, Québec, QC, Canada.
Denis VilleneuvePanacée Conseil, Québec, QC, Canada.
Clément BeaucageDirection régionale de la santé publique, Agence de la santé et des services sociaux de la Capitale-Nationale, Québec, QC, Canada.
Lilianne BordeleauChair on Adherence to Treatments, Université Laval, Québec, QC, Canada.
Sophie LauzierChair on Adherence to Treatments, Université Laval, Québec, QC, Canada. sophie.lauzier@pha.ulaval.ca.ORCID http://orcid.org/0000-0002-7746-9208
Hôpital du Saint-Sacrement · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Patients with an antidepressant drug treatment (ADT) report unmet needs and a significant proportion stop their ADT prematurely. Community pharmacists can play a key role in supporting these patients. Objective To explore the perspectives of various leaders in health care about the current and potential contributions of community pharmacists to patients on ADT. Setting The province of Quebec (Canada). Method We conducted a qualitative descriptive exploratory study using interviews among leaders who were involved in health care services, pharmaceutical services, physician and pharmacist education, as well as patient and healthcare professional associations. Verbatim transcripts of interviews were analyzed using computer-assisted thematic analysis. Main outcome measure Perspectives about the contributions of community pharmacists to patients on ADT. Results Interviews revealed that pharmacists are perceived to be accessible drug experts whose particular strengths are their thorough knowledge of drugs, their commitment to ensure ADT safety and tolerability, as well as their commitment to inform and support patients. Leaders trained in pharmacy or representatives of pharmacy organizations had concrete expectations for pharmacists' increased involvement in monitoring ADT adherence and efficacy. They extensively discussed the regulatory and organizational changes required to enhance this role. Leaders also stated that, in addition to patients, health care teams could benefit from pharmacists' expertise and support. Conclusion Participating key informants perceived the need for enhanced pharmacist monitoring of ADT adherence and efficacy. They also expressed their openness to an increased collaboration between health care teams and pharmacists.

Indexed as

PharmacistsProfessional-Patient RelationsProfessional RoleQualitative ResearchAntidepressive AgentsCommunity Pharmacy ServicesHealth PersonnelHumansQuebecAntidepressive AgentsAntidepressant agentsCanadaCommunity pharmacy servicesInterviewsKey informantsMedication therapy managementQualitative study

Identifiers

PMID28653260
OpenAlexW2679887763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.